Today: 8 June 2026
Browse Category

NASDAQ:CRSP 17 August 2025 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
CRISPR Therapeutics Stock Just Lost 12%: What Casgevy Must Prove Next

CRISPR Therapeutics Stock Just Lost 12%: What Casgevy Must Prove Next

CRISPR Therapeutics shares fell 11.6% Friday, closing at $48.79 with no new company disclosures. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. A June 4 shareholder meeting will vote on expanding the capital band and carrying forward a CHF 1.89 billion net loss. In March, CRISPR raised $536.3 million from a convertible notes offering.
25 April 2026
··
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
··
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics shares closed Friday at $55.08, down 2.87% in thin post-holiday trading. ARK Invest disclosed a purchase of 23,170 CRSP shares Friday, valued at about $1.31 million across its ARKK and ARKG ETFs. The broader market ended the session nearly flat, with major indexes little changed ahead of the new year.
27 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.
7 December 2025
····
CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics closed at $56.88 on December 5, giving the company a market cap near $5.9 billion. The State Board of Administration of Florida Retirement System disclosed a new $1.04 million stake. Q3 results showed a net loss of $106.4 million on $0.89 million in revenue. About 69% of shares are now held by institutions and hedge funds.
7 December 2025
··
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics shares surged 8.5% to $56 on December 3, landing mid-range between their 52-week low of $30 and high of $78. The company reported a $106 million Q3 net loss on $0.9 million in revenue but holds $1.9 billion in cash. Takeover rumors persist, though no formal bids have emerged. Wall Street price targets range widely, with consensus in the high-$60s to mid-$70s.
4 December 2025
·
Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK Invest bought 521,867 Pinterest shares across three funds after the stock fell over 20% on weak holiday-quarter guidance. The firm also added CRISPR Therapeutics and Beam Therapeutics shares earlier in the week. ARK sold 105,576 Roku shares and 56,095 Robinhood shares, and reduced its position in Teradyne. Pinterest projected Q4 revenue below consensus, citing softer ad spending and tougher competition.
6 November 2025
········
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Therapeutics shares plunged nearly 45% on Oct. 27 after the company halted two Phase 3 trials of its CRISPR therapy due to a patient suffering severe liver toxicity. The stock dropped from the mid-$20s to the low-teens, with NTLA trading around $14–15 as of midday Oct. 28. Several analysts downgraded the stock and cut price targets following the safety incident.
28 October 2025
···
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics traded near $67 on Oct. 27, down 3% after safety concerns hit gene-editing stocks. Shares remain up nearly 100% in 2025, fueled by a major preclinical breakthrough and global rollout of its Casgevy therapy. Rival Intellia plunged 45% after a trial pause, dragging CRSP down 10% in sympathy. Analysts remain bullish, with targets up to $93 despite sector volatility.
27 October 2025
··
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics shares traded near $69 in mid-October after rising about 40–45% over the past year. The company plans to raise up to $600 million in a new share offering announced October 15. Bank of America raised its price target to $93 and maintained a Buy rating. CRISPR reported preclinical success for CTX460 and continues to expand Casgevy’s commercial reach.
19 October 2025
···
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics (NASDAQ: CRSP) closed at $77.73 on Oct. 8, 2025, up 10% for the day and nearly 20% for the month. Trading volume reached 3.1 million shares, with the price moving between $70.77 and $78.38. The company’s market cap stood at $6.2 billion, and analysts’ average one-year price target was $81. CRSP remains pre-profit, reporting a Q2 net loss of $208.5 million on $0.9 million in revenue.
8 October 2025
·
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
1 2

Stock Market Today

  • Intesa Sanpaolo Sells 1000 MPS Shares at EUR 9.95 on Euronext Milan
    June 8, 2026, 3:20 PM EDT. Intesa Sanpaolo sold 1000 shares of Monte dei Paschi di Siena (MPS) on Euronext Milan for EUR 9.95 per share on June 8, 2026. The transaction reflects strategic asset adjustments by the Italian banking group amid market conditions. MPS shares trade on Euronext Milan, Italy's main stock exchange. This move could influence investor sentiment on both institutions.

Latest articles

Galaxy Digital spikes 24% as investors look at AI data center plans

Galaxy Digital spikes 24% as investors look at AI data center plans

8 June 2026
Galaxy Digital shares soared 23.6% to $31.07 after CEO Mike Novogratz said its West Texas AI data center—half of which is already leased—now represents more than half the company’s value, shifting focus from crypto to AI infrastructure; the stock’s surge outpaced bitcoin’s 2.7% rise as investors repriced Galaxy’s data-center business amid execution risks and strong analyst buy ratings.
Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

8 June 2026
Nu Holdings shares slid 3.1% to $11.60 as investors weighed CFO transition risks and rising credit costs, erasing last week’s 4.1% buyback-driven bounce; BofA downgraded the stock to Underperform with a $10 target, citing uncertainty from Lago’s exit, while Nu’s $1B buyback failed to stem a 10.7% weekly drop and 30.7% year-to-date decline, leaving shares just above their 52-week low.
Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

8 June 2026
Inno Holdings shares soared twentyfold to $20.97 after announcing a $3 million AI sales agent deal for its used mobile phone business, but investor risks remain with a recent $60 million at-the-market stock program and ongoing going-concern warnings in filings, as the project is still in early development and not yet commercially launched.
Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

8 June 2026
Emirates slashed June A380 flights on 10 major routes as soaring fuel costs and Middle East airspace disruption forced airlines to cut capacity, prompting IATA to halve its 2026 global profit forecast to $23 billion from $41 billion, with industry-wide seat reductions and rising fares expected as carriers struggle to absorb shocks during peak travel.
Wall Street Watches Microsoft’s $37 Billion AI Bet

Wall Street Watches Microsoft’s $37 Billion AI Bet

8 June 2026
Microsoft shares fell 1.5% to $410.30 as investors weighed bullish analyst calls and NHS England’s Copilot rollout against concerns that surging AI revenue—now at a $37 billion run rate—may not outpace rising costs and margin pressure from heavy infrastructure investment.
Go toTop